[Case Study] Analysis of Residual Solvents in Pharmaceuticals for Data Integrity Compliance

Added to bookmarks
Bookmarks list

Bookmark has been removed
Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.
Free membership registration

last updated：Jan 05, 2026

サーモフィッシャーサイエンティフィック株式会社／Thermo Fisher Scientific K.K.

Immediate start of residual solvent analysis in pharmaceuticals using the HS-GC/FID method with data integrity compliance.

Information has become increasingly diverse in recent years, and there is a growing demand for tools that can handle vast amounts of data accurately and conveniently. For example, analytical researchers may find it sufficient to obtain calibration curves and quantitative data from chromatograms and spectral information as chromatography data. However, it may be necessary to ensure that these data were obtained under conditions where the equipment operated correctly. Computerized systems used in the development and manufacturing of pharmaceuticals and medical devices must be properly developed, implemented, and operated, leaving evidence that proves there are no issues with the quality of the pharmaceuticals or medical devices, as well as their quality assurance. Computerized System Validation (CSV) is mandated by pharmaceutical regulations. Achieving Data Integrity (DI) requires essential support from software. This technical note outlines the overview of DI and the software functions required for DI, and introduces examples of residual solvent testing as specified in USP<467> using a headspace-specific autosampler and gas chromatograph that comply with DI.